Y40-Y59
Complications of medical and surgical care: Drugs, medicaments and biological substances causing adverse effects in therapeutic use
- Y40.0Adverse effects in therapeutic use, penicillins
- Y40.1Adverse effects in therapeutic use, cefalosporins and other beta-lactam antibiotics
- Y40.2Adverse effects in therapeutic use, chloramphenicol group
- Y40.3Adverse effects in therapeutic use, macrolides
- Y40.4Adverse effects in therapeutic use, tetracyclines
- Y40.5Adverse effects in therapeutic use, aminoglycosides
- Y40.6Adverse effects in therapeutic use, rifamycins
- Y40.7Adverse effects in therapeutic use, antifungal antibiotics, systemically used
- Y40.8Adverse effects in therapeutic use, other systemic antibiotics
- Y40.9Adverse effects in therapeutic use, systemic antibiotic, unspecified
- Y41.0Adverse effects in therapeutic use, sulfonamides
- Y41.1Adverse effects in therapeutic use, antimycobacterial drugs
- Y41.2Adverse effects in therapeutic use, antimalarials and drugs acting on other blood protozoa
- Y41.3Adverse effects in therapeutic use, other antiprotozoal drugs
- Y41.4Adverse effects in therapeutic use, anthelminthics
- Y41.5Adverse effects in therapeutic use, antiviral drugs
- Y41.8Adverse effects in therapeutic use, other specified systemic anti-infectives and antiparasitics
- Y41.9Adverse effects in therapeutic use, systemic anti-infectives and antiparasitics, unspecified
- Y42.0Adverse effects in therapeutic use, glucocorticoids and synthetic analogues
- Y42.1Adverse effects in therapeutic use, thyroid hormones and substitutes
- Y42.2Adverse effects in therapeutic use, antithyroid drugs
- Y42.3Adverse effects in therapeutic use, insulin and oral hypoglycaemic [antidiabetic] drugs
- Y42.4Adverse effects in therapeutic use, oral contraceptives
- Y42.5Adverse effects in therapeutic use, other estrogens and progestogens
- Y42.6Adverse effects in therapeutic use, antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified
- Y42.7Adverse effects in therapeutic use, androgens and anabolic congeners
- Y42.8Adverse effects in therapeutic use, other and unspecified hormones and their synthetic substitutes
- Y42.9Adverse effects in therapeutic use, other and unspecified hormone antagonists
- Y43.0Adverse effects in therapeutic use, antiallergic and antiemetic drugs
- Y43.1Adverse effects in therapeutic use, antineoplastic antimetabolites
- Y43.2Adverse effects in therapeutic use, antineoplastic natural products
- Y43.3Adverse effects in therapeutic use, other antineoplastic drugs
- Y43.4Adverse effects in therapeutic use, immunosuppressive agents
- Y43.5Adverse effects in therapeutic use, acidifying and alkalizing agents
- Y43.6Adverse effects in therapeutic use, enzymes, not elsewhere classified
- Y43.8Adverse effects in therapeutic use, other primarily systemic agents, not elsewhere classified
- Y43.9Adverse effects in therapeutic use, primarily systemic agent, unspecified
- Y44.0Adverse effects in therapeutic use, iron preparations and other anti-hypochromic-anaemia preparations
- Y44.1Adverse effects in therapeutic use, vitamin B12, folic acid and other anti-megaloblastic-anaemia preparations
- Y44.2Adverse effects in therapeutic use, anticoagulants
- Y44.3Adverse effects in therapeutic use, anticoagulant antagonists, vitamin K and other coagulants
- Y44.4Adverse effects in therapeutic use, antithrombotic drugs [platelet-aggregation inhibitors]
- Y44.5Adverse effects in therapeutic use, thrombolytic drugs
- Y44.6Adverse effects in therapeutic use, natural blood and blood products
- Y44.7Adverse effects in therapeutic use, plasma substitutes
- Y44.9Adverse effects in therapeutic use, other and unspecified agents affecting blood constituents
- Y45.0Adverse effects in therapeutic use, opioids and related analgesics
- Y45.1Adverse effects in therapeutic use, salicylates
- Y45.2Adverse effects in therapeutic use, propionic acid derivatives
- Y45.3Adverse effects in therapeutic use, other nonsteroidal anti-inflammatory drugs [NSAID]
- Y45.4Adverse effects in therapeutic use, antirheumatics
- Y45.5Adverse effects in therapeutic use, 4-aminophenol derivatives
- Y45.8Adverse effects in therapeutic use, other analgesics and antipyretics
- Y45.9Adverse effects in therapeutic use, analgesic, antipyretic and anti-inflammatory drug, unspecified
- Y46.0Adverse effects in therapeutic use, succinimides
- Y46.1Adverse effects in therapeutic use, oxazolidinediones
- Y46.2Adverse effects in therapeutic use, hydantoin derivatives
- Y46.3Adverse effects in therapeutic use, deoxybarbiturates
- Y46.4Adverse effects in therapeutic use, iminostilbenes
- Y46.5Adverse effects in therapeutic use, valproic acid
- Y46.6Adverse effects in therapeutic use, other and unspecified antiepileptics
- Y46.7Adverse effects in therapeutic use, antiparkinsonism drugs
- Y46.8Adverse effects in therapeutic use, antispasticity drugs
- Y47.0Adverse effects in therapeutic use, barbiturates, not elsewhere classified
- Y47.1Adverse effects in therapeutic use, benzodiazepines
- Y47.2Adverse effects in therapeutic use, cloral derivatives
- Y47.3Adverse effects in therapeutic use, paraldehyde
- Y47.4Adverse effects in therapeutic use, bromine compounds
- Y47.5Adverse effects in therapeutic use, mixed sedatives and hypnotics, not elsewhere classified
- Y47.8Adverse effects in therapeutic use, other sedatives, hypnotics and antianxiety drugs
- Y47.9Adverse effects in therapeutic use, sedative, hypnotic and antianxiety drug, unspecified
- Y48.0Adverse effects in therapeutic use, inhaled anaesthetics
- Y48.1Adverse effects in therapeutic use, parenteral anaesthetics
- Y48.2Adverse effects in therapeutic use, other and unspecified general anaesthetics
- Y48.3Adverse effects in therapeutic use, local anaesthetics
- Y48.4Adverse effects in therapeutic use, anaesthetic, unspecified
- Y48.5Adverse effects in therapeutic use, therapeutic gases
- Y49.0Adverse effects in therapeutic use, tricyclic and tetracyclic antidepressants
- Y49.1Adverse effects in therapeutic use, monoamine-oxidase-inhibitor antidepressants
- Y49.2Adverse effects in therapeutic use, other and unspecified antidepressants
- Y49.3Adverse effects in therapeutic use, phenothiazine antipsychotics and neuroleptics
- Y49.4Adverse effects in therapeutic use, butyrophenone and thioxanthene neuroleptics
- Y49.5Adverse effects in therapeutic use, other antipsychotics and neuroleptics
- Y49.6Adverse effects in therapeutic use, psychodysleptics [hallucinogens]
- Y49.7Adverse effects in therapeutic use, psychostimulants with abuse potential
- Y49.8Adverse effects in therapeutic use, other psychotropic drugs, not elsewhere classified
- Y49.9Adverse effects in therapeutic use, psychotropic drug, unspecified
- Y50.0Adverse effects in therapeutic use, analeptics
- Y50.1Adverse effects in therapeutic use, opioid receptor antagonists
- Y50.2Adverse effects in therapeutic use, methylxanthines, not elsewhere classified
- Y50.8Adverse effects in therapeutic use, other central nervous system stimulants
- Y50.9Adverse effects in therapeutic use, central nervous system stimulant, unspecified
- Y51.0Adverse effects in therapeutic use, anticholinesterase agents
- Y51.1Adverse effects in therapeutic use, other parasympathomimetics [cholinergics]
- Y51.2Adverse effects in therapeutic use, ganglionic blocking drugs, not elsewhere classified
- Y51.3Adverse effects in therapeutic use, other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, not elsewhere classified
- Y51.4Adverse effects in therapeutic use, predominantly alpha-adrenoreceptor agonists, not elsewhere classified
- Y51.5Adverse effects in therapeutic use, predominantly beta-adrenoreceptor agonists, not elsewhere classified
- Y51.6Adverse effects in therapeutic use, alpha-adrenoreceptor antagonists, not elsewhere classified
- Y51.7Adverse effects in therapeutic use, beta-adrenoreceptor antagonists, not elsewhere classified
- Y51.8Adverse effects in therapeutic use, centrally acting and adrenergic-neuron-blocking agents, not elsewhere classified
- Y51.9Adverse effects in therapeutic use, other and unspecified drugs primarily affecting the autonomic nervous system
- Y52.0Adverse effects in therapeutic use, cardiac-stimulant glycosides and drugs of similar action
- Y52.1Adverse effects in therapeutic use, calcium-channel blockers
- Y52.2Adverse effects in therapeutic use, other antidysrhythmic drugs, not elsewhere classified
- Y52.3Adverse effects in therapeutic use, coronary vasodilators, not elsewhere classified
- Y52.4Adverse effects in therapeutic use, angiotensin-converting-enzyme inhibitors
- Y52.5Adverse effects in therapeutic use, other antihypertensive drugs, not elsewhere classified
- Y52.6Adverse effects in therapeutic use, antihyperlipidaemic and antiarteriosclerotic drugs
- Y52.7Adverse effects in therapeutic use, peripheral vasodilators
- Y52.8Adverse effects in therapeutic use, antivaricose drugs, including sclerosing agents
- Y52.9Adverse effects in therapeutic use, other and unspecified agents primarily affecting the cardiovascular system
- Y53.0Adverse effects in therapeutic use, histamine H2-receptor antagonists
- Y53.1Adverse effects in therapeutic use, other antacids and anti-gastric-secretion drugs
- Y53.2Adverse effects in therapeutic use, stimulant laxatives
- Y53.3Adverse effects in therapeutic use, saline and osmotic laxatives
- Y53.4Adverse effects in therapeutic use, other laxatives
- Y53.5Adverse effects in therapeutic use, digestants
- Y53.6Adverse effects in therapeutic use, antidiarrhoeal drugs
- Y53.7Adverse effects in therapeutic use, emetics
- Y53.8Adverse effects in therapeutic use, other agents primarily affecting the gastrointestinal system
- Y53.9Adverse effects in therapeutic use, agent primarily affecting the gastrointestinal system, unspecified
- Y54.0Adverse effects in therapeutic use, mineralocorticoids
- Y54.1Adverse effects in therapeutic use, mineralocorticoid antagonists [aldosterone antagonists]
- Y54.2Adverse effects in therapeutic use, carbonic-anhydrase inhibitors
- Y54.3Adverse effects in therapeutic use, benzothiadiazine derivatives
- Y54.4Adverse effects in therapeutic use, loop [high-ceiling] diuretics
- Y54.5Adverse effects in therapeutic use, other diuretics
- Y54.6Adverse effects in therapeutic use, electrolytic, caloric and water-balance agents
- Y54.7Adverse effects in therapeutic use, agents affecting calcification
- Y54.8Adverse effects in therapeutic use, agents affecting uric acid metabolism
- Y54.9Adverse effects in therapeutic use, mineral salts, not elsewhere classified
- Y55.0Adverse effects in therapeutic use, oxytocic drugs
- Y55.1Adverse effects in therapeutic use, skeletal muscle relaxants [neuromuscular blocking agents]
- Y55.2Adverse effects in therapeutic use, other and unspecified agents primarily acting on muscles
- Y55.3Adverse effects in therapeutic use, antitussives
- Y55.4Adverse effects in therapeutic use, expectorants
- Y55.5Adverse effects in therapeutic use, anti-common-cold drugs
- Y55.6Adverse effects in therapeutic use, antiasthmatics, not elsewhere classified
- Y55.7Adverse effects in therapeutic use, other and unspecified agents primarily acting on the respiratory system
- Y56.0Adverse effects in therapeutic use, local antifungal, anti-infective and anti-inflammatory drugs, not elsewhere classified
- Y56.1Adverse effects in therapeutic use, antipruritics
- Y56.2Adverse effects in therapeutic use, local astringents and local detergents
- Y56.3Adverse effects in therapeutic use, emollients, demulcents and protectants
- Y56.4Adverse effects in therapeutic use, keratolytics, keratoplastics and other hair treatment drugs and preparations
- Y56.5Adverse effects in therapeutic use, ophthalmological drugs and preparations
- Y56.6Adverse effects in therapeutic use, otorhinolaryngological drugs and preparations
- Y56.7Adverse effects in therapeutic use, dental drugs, topically applied
- Y56.8Adverse effects in therapeutic use, other topical agents
- Y56.9Adverse effects in therapeutic use, topical agent, unspecified
- Y57.0Adverse effects in therapeutic use, appetite depressants [anorectics]
- Y57.1Adverse effects in therapeutic use, lipotropic drugs
- Y57.2Adverse effects in therapeutic use, antidotes and chelating agents, not elsewhere classified
- Y57.3Adverse effects in therapeutic use, alcohol deterrents
- Y57.4Adverse effects in therapeutic use, pharmaceutical excipients
- Y57.5Adverse effects in therapeutic use, X-ray contrast media
- Y57.6Adverse effects in therapeutic use, other diagnostic agents
- Y57.7Adverse effects in therapeutic use, vitamins, not elsewhere classified
- Y57.8Adverse effects in therapeutic use, other drugs and medicaments
- Y57.9Adverse effects in therapeutic use, drug or medicament, unspecified
- Y58.0Adverse effects in therapeutic use, BCG vaccine
- Y58.1Adverse effects in therapeutic use, typhoid and paratyphoid vaccine
- Y58.2Adverse effects in therapeutic use, cholera vaccine
- Y58.3Adverse effects in therapeutic use, plague vaccine
- Y58.4Adverse effects in therapeutic use, tetanus vaccine
- Y58.5Adverse effects in therapeutic use, diphtheria vaccine
- Y58.6Adverse effects in therapeutic use, pertussis vaccine, including combinations with a pertussis component
- Y58.8Adverse effects in therapeutic use, mixed bacterial vaccines, except combinations with a pertussis component
- Y58.9Adverse effects in therapeutic use, other and unspecified bacterial vaccines
- Y59.0Adverse effects in therapeutic use, viral vaccines
- Y59.1Adverse effects in therapeutic use, rickettsial vaccines
- Y59.2Adverse effects in therapeutic use, protozoal vaccines
- Y59.3Adverse effects in therapeutic use, immunoglobulin
- Y59.8Adverse effects in therapeutic use, other specified vaccines and biological substances
- Y59.9Adverse effects in therapeutic use, vaccine or biological substance, unspecified